1. Lebensztejn DM, Flisiak-Jackiewicz M, BiałokozKalinowska I, Bobrus-Chociej A, Kowalska I.
Hepatokines and non-alcoholic fatty liver disease.
Acta Biochim Pol. 2016;63(3):459-67.
2. de Oliveira Dos Santos AR, de Oliveira Zanuso B,
Miola VFB, Barbalho SM, Santos Bueno PC, Flato
UAP, Detregiachi CRP, Buchaim DV, Buchaim RL,
Tofano RJ, Mendes CG, Tofano VAC, Dos Santos
Haber JF. Adipokines, Myokines, and Hepatokines:
Crosstalk and Metabolic Repercussions. Int J Mol Sci.
2021 Mar 5;22(5):2639.
3. Farkhondeh T, Llorens S, Pourbagher-Shahri AM,
Ashrafizadeh M, Talebi M, Shakibaei M, et al. An
overview of the role of adipokines in cardiometabolic
diseases. Molecules. 2020;25(21):5218.
4. Abdullah A, Peeters A, de Courten M, Stoelwinder J.
The magnitude of association between overweight and
obesity and the risk of diabetes: a meta-analysis of
prospective cohort studies. Diabetes Res Clin Pract.
2010;89(3):309-19.
5. Flegal KM. Carroll MD, Kuczmarski RJ, Johnson CL.
Overweight and obesity in the United States:
prevalence and trends. 1960;1994:39-47.
6. Hotamisligil GS. Inflammation and metabolic
disorders. Nature. 2006;444(7121):860-7.
7. Verduci E, Calcaterra V, Di Profio E, Fiore G, Rey F,
Magenes VC, et al. Brown adipose tissue: new
challenges for prevention of childhood obesity. a
narrative review. Nutrients. 2021;13(5):1450.
8. Misu H, Takamura T, Matsuzawa N, Shimizu A, Ota
T, Sakurai M, et al. Genes involved in oxidative
phosphorylation are coordinately upregulated with
fasting hyperglycaemia in livers of patients with type
2 diabetes. Diabetologia. 2007;50(2):268-77.
9. Misu H. Pathophysiological significance of
hepatokine overproduction in type 2 diabetes.
Diabetol Int. 2018;9(4):224-33.
10. Kershaw EE, Flier JS. Adipose tissue as an
endocrine organ. J Clin Endocrinol Metab. 2004
Jun;89(6):2548-56
11. Badman MK, Flier JS. The adipocyte as an active
participant in energy balance and metabolism.
Gastroenterology. 2007;132(6):2103-15.
12. Corgosinho FC, de Piano A, Sanches PL, Campos
RM, Silva PL, Carnier J, et al. The role of PAI-1 and
adiponectin on the inflammatory state and energy
balance in obese adolescents with metabolic
syndrome. Inflammation. 2012;35(3):944-51.
13. Ha H, Oh EY, Lee HB. The role of plasminogen
activator inhibitor 1 in renal and cardiovascular
diseases. Nat Rev Nephrol. 2009;5(4):203-11.
14. Loskutoff DJ, van Mourik JA, Erickson LA,
Lawrence D. Detection of an unusually stable
fibrinolytic inhibitor produced by bovine endothelial
cells. Proc Natl Acad Sci U S A. 1983;80(10):2956-
60.
15. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl
P, Krebs M, et al. Plasminogen activator inhibitor 1:
physiological and pathophysiological roles. Physiol.
2002;17(2):56-61.
16. Ghosh AK, Vaughan DE. PAI‐1 in tissue fibrosis. J
Cell Physiol.. 2012;227(2):493-507.
17. Kubala MH, DeClerck YA. The plasminogen
activator inhibitor-1 paradox in cancer: a mechanistic
understanding. Cancer Metastasis Rev.
2019;38(3):483-92.
18. Declerck PJ, Gils A. Three decades of research on
plasminogen activator inhibitor-1: a multifaceted
serpin. Semin Thromb Hemost. 2013;39(4):356-64
19. Liu RM. Oxidative stress, plasminogen activator
inhibitor 1, and lung fibrosis. Antioxid Redox Signal.
2008 Feb;10(2):303-19.
20. Alsharoh H, Ismaiel A, Leucuta DC, Popa SL,
Dumitrascu DL. Plasminogen Activator Inhibitor-1
Levels in Non-alcoholic Fatty Liver Disease: A
Systematic Review and Meta-Analysis. J
Gastrointestin Liver Dis. 2022 Jun 12;31(2):206-214.
21.Gnacinska M, Malgorzewicz S, Stojek M, LysiakSzydlowska W, Sworczak K. Role of adipokines in
complications related to obesity. A review. Adv Med
Sci. 2009;54(2):150.
22. Serag Esmat RF, Rashed L. Effect of exercise on
plasminogen activator inhibitor-1 (PAI-1) level in
patients with metabolic syndrome. J Am Sci.
2010;6(12).
23. Bodary PF, Yasuda N, Watson DD, Brown AS,
Davis JM, Pate RR. Effects of short-term exercise
training on plasminogen activator inhibitor (PAI-1).
Med Sci Sports Exerc. 2003;35(11):1853-8.
24. Pollock ML, Franklin BA, Balady GJ, Chaitman BL,
Fleg JL, Fletcher B, et al. Resistance exercise in
individuals with and without cardiovascular disease:
benefits, rationale, safety, and prescriptionan advisory
from the committee on exercise, rehabilitation, and
prevention, council on clinical cardiology, american
heart association. Circulation. 2000;101(7):828-33.
25. Pescatello LS, Franklin BA, Fagard R, Farquhar
WB, Kelley GA, Ray CA. American College of Sports
Medicine position stand. Exercise and hypertension.
Med Sci Sports Exerc. 2004;36(3):20.
26. Khademi, Tawfighi, Toloui Azar, Seifi Nabi Abad,
Haider, Nouri Habashi. The effect of aerobic and
resistance training on some coagulation factors (PAI1, fibrinogen, PT, PTT) and fibrinolysis (tPA,
plasminogen, didimer) in sedentary obese women.
Sports Biol J. 2021;13(1):39-57 [in Persion]
27. Smith DL, Fernhall B. Advanced cardiovascular
exercise physiology: Human Kinetics; 2011.
28. Bacon SL, Pelletier R, Lavoie KL. The impact of
acute and chronic exercise on thrombosis in
cardiovascular disease. Thromb Haemost.
2009;101(03):452-9.
29. Chen Y-W, Apostolakis S, Lip GY. Exerciseinduced changes in inflammatory processes:
Implications for thrombogenesis in cardiovascular
disease. Ann Med.2014;46(7):439-55.
30. Dawson S, Wiman B, Hamsten A, Green F,
Humphries S, Henney A. The two allele sequences of
a common polymorphism in the promoter of the
plasminogen activator inhibitor-1 (PAI-1) gene
respond differently to interleukin-1 in HepG2 cells. J
Biol Chemistry. 1993;268(15):10739-45.
مجله علوم پزشکی پارس